BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, announced a significant insider purchase by its Chairman and CEO, Jason Matuszewski.
On August 19, 2025, Matuszewski acquired 15,500 shares through two transactions: 2,500 shares at $6.28 and 13,000 shares at $6.51, totaling approximately $100,000. Following these purchases, his total ownership stands at 1,145,362 shares.
BioStem Technologies (OTC: BSEM), azienda MedTech specializzata in prodotti derivati dalla placenta per la cura avanzata delle ferite, ha comunicato un importante acquisto interno da parte del suo Presidente e CEO, Jason Matuszewski.
Il 19 agosto 2025 Matuszewski ha acquisito 15.500 azioni in due operazioni: 2.500 azioni a $6,28 e 13.000 azioni a $6,51, per un valore complessivo di circa $100.000. Dopo questi acquisti, la sua partecipazione totale 猫 di 1.145.362 azioni.
BioStem Technologies (OTC: BSEM), una empresa MedTech especializada en productos derivados de la placenta para el cuidado avanzado de heridas, anunci贸 una compra interna significativa realizada por su presidente y CEO, Jason Matuszewski.
El 19 de agosto de 2025, Matuszewski adquiri贸 15.500 acciones en dos transacciones: 2.500 acciones a $6,28 y 13.000 acciones a $6,51, por un total aproximado de $100,000. Tras estas compras, su propiedad total asciende a 1.145.362 acciones.
BioStem Technologies (OTC: BSEM), 靸侅矘 旃橂毳� 鞙勴暅 韮滊皹 鞙犽灅 鞝滍拡鞚� 鞝勲鞙茧 頃橂姅 氅旊摐韰岉伂 須岇偓電� 鞚挫偓鞛� 瓴� CEO 鞝滌澊鞀� 毵堩埇鞝滍攧鞀ろ偆(Jason Matuszewski)鞚� 雮措秬鞛� 欤检嫕 毵れ瀰鞚� 瓿奠頄堨姷雼堧嫟.
2025雲� 8鞗� 19鞚�, 毵堩埇鞝滍攧鞀ろ偆電� 霊� 瓯挫潣 瓯半灅搿� 15,500欤�毳� 旆摑頄堨姷雼堧嫟: 2,500欤茧ゼ 欤茧嫻 $6.28鞐�, 13,000欤茧ゼ 欤茧嫻 $6.51鞐� 毵れ垬頃橃棳 齑� 鞎� $100,000鞚� 歆�攵堩枅鞀惦媹雼�. 鞚� 毵れ瀰 頉� 攴胳潣 齑� 氤挫湢 欤检嫕鞚� 1,145,362欤�鞛呺媹雼�.
BioStem Technologies (OTC: BSEM), une soci茅t茅 MedTech sp茅cialis茅e dans les produits d茅riv茅s du placenta pour les soins avanc茅s des plaies, a annonc茅 un achat d'initi茅 important r茅alis茅 par son pr茅sident et PDG, Jason Matuszewski.
Le 19 ao没t 2025, Matuszewski a acquis 15 500 actions lors de deux transactions : 2 500 actions 脿 $6,28 et 13 000 actions 脿 $6,51, pour un total d'environ $100 000. Apr猫s ces achats, sa d茅tention totale s'茅l猫ve 脿 1 145 362 actions.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf plazentabasierte Produkte f眉r die fortgeschrittene Wundversorgung spezialisiert hat, meldete einen bedeutenden Insiderkauf durch seinen Vorsitzenden und CEO Jason Matuszewski.
Am 19. August 2025 erwarb Matuszewski 15.500 Aktien in zwei Transaktionen: 2.500 Aktien zu $6,28 und 13.000 Aktien zu $6,51, insgesamt rund $100.000. Nach diesen K盲ufen bel盲uft sich sein Gesamtbestand auf 1.145.362 Aktien.
- CEO demonstrates confidence in company through $100,000 personal investment
- Significant insider ownership with CEO holding over 1.1 million shares
- Multiple purchase transactions showing sustained buying interest
- None.
POMPANO BEACH, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, discloses an insider purchase of common stock from Jason Matuszewski, Chairman and Chief Executive Officer of BioStem Technologies.
Mr. Matuszewski purchased a total of 15,500 shares on August 19, 2025, totaling approximately
For more information about the purchases, please visit the OTCID disclosure website under .
About BioStem Technologies, Inc.聽(OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain庐听processing method. BioREtain庐听has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies鈥� quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (鈥淎ATB鈥�). These systems and procedures are established per current Good Tissue Practices (鈥渃GTP鈥�) and current Good Manufacturing Processes (鈥渃GMP鈥�). Our portfolio of quality brands includes AmnioWrap2鈩�, VENDAJE庐, VENDAJE AC庐, and VENDAJE OPTIC庐. Each BioStem Technologies placental allograft is processed at the Company鈥檚 FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on and .
Join BioStem鈥檚 Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company鈥檚 email distribution list , and follow us on and .
Contact BioStem Technologies, Inc.:
Website:
E-Mail:
X:
Facebook:
Phone: 954-380-8342
Investor Relations:
Adam Holdsworth, BioStem Director of Investor Relations
E-Mail:
笔丑辞苍别:听917-497-9287
Or
Gilmartin Group
Philip Trip Taylor, Principal
E-Mail:
Phone: 415-937-5406
FAQ
How many shares did BioStem Technologies (BSEM) CEO purchase in August 2025?
What is the total stock ownership of BioStem Technologies CEO after the recent purchase?
At what price did the BSEM CEO purchase company shares?
What does BioStem Technologies (BSEM) specialize in?
